NEW YORK (GenomeWeb News) – Proteomics tools developer AB Sciex said today that it is collaborating with Mount Sinai Hospital's research institute in Toronto to study proteins involved in cancer, diabetes, and heart disease.
Mount Sinai's Samuel Lunenfeld Research Institute is using an emerging mass spectrometry platform that is being developed by AB Sciex to analyze complex protein interactions and modifications in the pathways and processes involved in cellular communication. AB Sciex said that the new platform "combines qualitative and quantitative analysis at high resolution, high speed, and high sensitivity with accurate mass."
The collaboration with the Lunenfeld scientists also will help AB Sciex develop new workflows and applications that will be available when the mass spec platform is launched sometime later this year.
"Through the development of workflows and applications, we will be able to deliver more effective ways of working that will be available on the industry's most unique mass spectrometry platform." AB Sciex VP and GM of Pharmaceuticals and Proteomics Dave Hicks said in a statement.